Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi Sells 3,195 Shares

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 3,195 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $26.61, for a total value of $85,018.95. Following the sale, the chief financial officer now owns 148,509 shares of the company’s stock, valued at $3,951,824.49. This represents a 2.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Balaji Gandhi also recently made the following trade(s):

• On Tuesday, October 15th, Balaji Gandhi sold 864 shares of Phreesia stock. The stock was sold at an average price of $21.03, for a total transaction of $18,169.92.

Phreesia Stock Performance

Phreesia stock opened at $26.75 on Friday. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $29.16. The company has a current ratio of 1.74, a quick ratio of 1.77 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.55 billion, a P/E ratio of -18.20 and a beta of 0.94. The stock has a 50 day moving average of $22.87 and a 200-day moving average of $22.62.

Phreesia (NYSE:PHR) last posted its quarterly earnings data on Monday, December 9th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. The firm had revenue of $106.80 million for the quarter, compared to the consensus estimate of $106.33 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The firm’s revenue was up 16.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.58) EPS. On average, analysts expect that Phreesia, Inc. will post -1.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on PHR shares. JMP Securities reiterated a “market outperform” rating and set a $30.00 price objective on shares of Phreesia in a research note on Tuesday, December 10th. Truist Financial increased their price target on Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Needham & Company LLC restated a “buy” rating and set a $29.00 price objective on shares of Phreesia in a research note on Friday. KeyCorp increased their target price on Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Robert W. Baird reduced their price target on Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. Twelve analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $31.00.

Institutional Trading of Phreesia

Hedge funds and other institutional investors have recently bought and sold shares of the company. Franklin Resources Inc. lifted its holdings in Phreesia by 3.0% during the 3rd quarter. Franklin Resources Inc. now owns 1,497,631 shares of the company’s stock worth $31,495,000 after buying an additional 42,973 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Phreesia by 4.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,245,797 shares of the company’s stock valued at $28,397,000 after acquiring an additional 55,934 shares in the last quarter. M&T Bank Corp lifted its stake in Phreesia by 4.6% during the third quarter. M&T Bank Corp now owns 35,127 shares of the company’s stock worth $801,000 after purchasing an additional 1,535 shares during the last quarter. Barclays PLC boosted its holdings in Phreesia by 83.6% in the third quarter. Barclays PLC now owns 94,929 shares of the company’s stock worth $2,163,000 after purchasing an additional 43,225 shares during the period. Finally, XTX Topco Ltd bought a new stake in Phreesia during the third quarter valued at $247,000. 92.10% of the stock is owned by institutional investors.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.